MTIP Inhibitor Quorum Sensing Blockade for Pseudomonas Virulence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for infections caused by Pseudomonas aeruginosa, which utilize the 5′-methylthioinosine phosphorylase (MTIP) in quorum sensing pathways, face challenges due to antimicrobial resistance and the need for non-lethal, non-resistance-inducing therapeutic approaches.
Innovation Solution
Administration of a sub-growth inhibiting amount of a 5′-methylthioinosine phosphorylase (MTIP) inhibitor to reduce bacterial virulence without promoting resistance, targeting the quorum sensing pathway in bacteria like Pseudomonas aeruginosa, Pseudomonas syringae, and Xanthomonas campestris.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antimicrobial treatments are used to treat Pseudomonas aeruginosa infections, then bacterial growth is inhibited, but antimicrobial resistance develops
Solution Approach 1:
The patent extracts the quorum sensing pathway as a separate target from conventional antimicrobial action. By specifically inhibiting MTIP enzymes in the quorum sensing pathway rather than targeting bacterial cell growth directly, the treatment achieves effectiveness while avoiding the selection pressure that drives antimicrobial resistance.
Solution Approach 2:
The patent changes the therapeutic parameter from direct antimicrobial growth inhibition to quorum sensing pathway inhibition. This parameter change allows the treatment to affect bacterial virulence and persistence without killing the bacteria, thereby avoiding the development of antimicrobial resistance.
2Productivity
If lethal antimicrobial treatments are used, then bacterial growth is suppressed, but drug resistance is promoted
Solution Approach 1:
Instead of using lethal antimicrobials that kill or suppress bacterial growth, the patent inverts the approach by using sub-growth inhibiting amounts of MTIP inhibitors. This inversion allows the treatment to disrupt quorum sensing and reduce virulence without causing bacterial death, thereby avoiding the selection for resistant mutants.
Solution Approach 2:
The patent applies partial action by using sub-growth inhibiting amounts of the MTIP inhibitor rather than full growth suppression. This partial inhibition of the quorum sensing pathway is sufficient to reduce virulence and attenuation infection severity, while avoiding the excessive action that would select for resistant bacteria.
3Object-generated harmful factors
If quorum sensing blockade is used, then virulence is attenuated without affecting bacterial growth, but treatment effectiveness must be maintained
Solution Approach 1:
The patent employs feedback mechanisms to ensure treatment effectiveness. By monitoring quorum sensing pathway activity and adjusting MTIP inhibitor dosing, the treatment maintains effective virulence attenuation while preserving bacterial growth for continued quorum sensing disruption, preventing the development of resistance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MTIP inhibitor effectively reduces bacterial virulence by inhibiting quorum sensing, thereby attenuating infection severity without inducing drug resistance, providing a novel approach to treating infections caused by these bacteria.
Implementation Method 1
administration of a sub-growth inhibiting amount of a 5′-methylthioinosine phosphorylase (MTIP) inhibitor to reduce bacterial virulence
Data Source
AI summary
The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5′-methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.